2017-10-04 08:30:00

Oasmia Pharmaceutical AB Announces Resignation of its Chief Financial Officer


Oasmia Pharmaceutical AB
Inside information

Oasmia Pharmaceutical AB Announces Resignation of its Chief Financial Officer

Uppsala, Sweden, 2017-10-04 08:30 CEST (GLOBE NEWSWIRE) -- Oasmia
Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs
within human and veterinary oncology has announced that the Company’s Chief
Financial Officer, Fredrik Gynnerstedt, has decided in mutual agreement with
the Company to end his employment, effective immediately.

In the interim, Oasmia appoints Anders Blom, Executive Vice President as
temporary CFO.



About Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB develops, manufactures, markets and sells new
generations of drugs in the field of human and veterinary oncology. The
company’s product development aims to create and manufacture novel nanoparticle
formulations and drug-delivery systems based on well-established cytostatics
which, in comparison with current alternatives, show improved properties,
reduced side-effects, and expanded applications. The company’s product
development is based on its proprietary in-house research and company patents.
Oasmia is listed on NASDAQ Capital Markets (OASM.US), Frankfurt Stock Exchange
(OMAX.GR, ISIN SE0000722365) and NASDAQ Stockholm (OASM.ST).


For more information, please contact:
Julian Aleksov, Executive Chairman
Tel : +4618 - 50 54 40
E-mail: julian.aleksov@oasmia.com


Attached html: HTML
Attached pdf: PDF